AL amyloidosis phase III clinical trial of birtamimab fails to meet primary endpoint
Prothena, the pharmaceutical company that produce the AL amyloidosis drug birtamimab, have announced that the Phase III AFFIRM-AL clinical trial failed to meet its primary endpoint – i.e., the main result being measured in the…